Chronic Lymphocytic Leukemia: Identification of Novel Prognostic Markers and Their Clinical Application

Dear Colleagues,

Chronic lymphocytic leukemia (CLL), the most common leukemia in the Western Hemisphere, is characterized by the accumulation of malignant, mature-appearing B-lymphocytes in blood, bone marrow, and lymph nodes. The disease course is highly variable; some patients develop rapidly progressive disease, while others have an indolent course that spans decades. Identification of novel prognostic markers and their clinical application is an important area of research in CLL. Prognostic markers are used to predict the disease course and the likelihood of response to treatment. In recent years, significant progress has been made in identifying and implementing new prognostic markers. These include immunophenotypic and molecular genetic markers, including recurrent chromosomal abnormalities, gene mutations, and epigenetic alterations. This research has enhanced our understanding of the disease’s pathogenesis and our ability to predict the prognosis of individual patients. Ultimately, the identification of new prognostic markers will help to guide treatment decisions and improve outcomes for patients with CLL.

Prof. Dr. Lynne V. Abruzzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• chronic lymphocytic leukemia (CLL)
• prognostic markers
• clinical application
• response
• treatment